Chinese experts consensus on the optimized application of PET imaging in the diagnosis of dementia(2021 edition)

doi:10.3969/j.issn.1672-6731.2021.11.002

Abstract

Abstract:

Dementia is a serious global public health problem, especially with the aging of the population. Its incidence will further increase. The onset of dementia is insidious, and the diagnostic framework characterized by clinical symptoms is less effective in practice. Biomarker has improved the accuracy of dementia diagnosis. PET imaging can reflect the pathological process of dementia in vivo and is an important imaging biomarker for the diagnosis of dementia. With the rapid increase in the number of PET equipment in large medical institutions, PET assessment for dementia patients has been gradually carried out during clinical diagnosis and treatment, but the current evidence of PET imaging in dementia still needs further research and improvement. So, it is necessary to plan a reasonable clinical dementia PET application guide based on the existing research evidence and the actual situation to optimize its application for the diagnosis of dementia.

Key words: Dementia, Positron-emission tomography, Expert consensus (not in MeSH), China

摘要：

痴呆是一项严重的世界性公共卫生难题，特别是随着人口老龄化的进程，其发病率逐渐升高。痴呆发病较为隐匿，以临床症状为特征的诊断框架在实际操作中效能较低，影像学标志物证据引入诊断系统使痴呆诊断的准确性大幅度提高。PET显像可以在体反映痴呆的病理学过程，是痴呆诊断的重要影像学标志物。随着国内PET设备在大型医疗机构的保有量迅速增长，临床诊疗过程中逐步开展针对痴呆患者的PET显像，但目前PET显像在痴呆中的应用证据尚待进一步完善。因此有必要在现有证据的基础上结合临床实践制定合理的临床痴呆诊断中PET应用中国专家共识，规范其在痴呆诊断中的应用。

关键词: 痴呆, 正电子发射断层显像术, 专家共识(非MeSH词), 中国

Congress of Neuro-Degenerative Diseases Committee of the Chinese Society of Microcirculation. Chinese experts consensus on the optimized application of PET imaging in the diagnosis of dementia(2021 edition)[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2021, 21(11): 918-926.

中国微循环学会神经变性病专业委员会. 痴呆诊断中PET临床合理化应用中国专家共识（2021版）[J]. 中国现代神经疾病杂志, 2021, 21(11): 918-926.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2021.11.002

https://journal11.magtechjournal.com/cjcnn/EN/Y2021/V21/I11/918

References

[1] The epidemiology and impact of dementia:current state and future trends, 2015[EB/OL].[2021-03-08]. http://www.who.int/mental_health/neurology/dementia/dementia_thematicbrief_epidemiology.pdf.
[2] Dementia, 2017[EB/OL].[2021-03-08]. http://www.who.int/mediacentre/factsheets/fs362/en/.
[3] Dementia:number of people affected to triple in next 30 years, 2017[EB/OL].[2021-03-08]. http://www.who.int/mediacentre/news/releases/2017/dementia-triple-affected/en/.
[4] Grand JH, Caspar S, Macdonald SW. Clinical features and multidisciplinary approaches to dementia care[J]. J Multidiscip Healthc, 2011, 4:125-147.
[5] Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors. NIA-AA research framework:toward a biological definition of Alzheimer's disease[J]. Alzheimers Dement, 2018, 14:535-562.
[6] Gomperts SN, Marquie M, Locascio JJ, Bayer S, Johnson KA, Growdon JH. PET radioligands reveal the basis of dementia in Parkinson's disease and dementia with lewy bodies[J]. Neurodegener Dis, 2016, 16:118-124.
[7] Matsunari I, Samuraki M, Chen WP, Yanase D, Takeda N, Ono K, Yoshita M, Matsuda H, Yamada M, Kinuya S. Comparison of ¹⁸F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer's disease:aging effect on diagnostic performance[J]. J Nucl Med, 2007, 48:1961-1970.
[8] Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia[J]. J Neurol Neurosurg Psychiatry, 1999, 66:184-188.
[9] Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, Chatterjee A, Hurtig HI, Karlawish JH, Rosen HJ, Van Deerlin V, Lee VM, Miller BL, Trojanowski JQ, Grossman M. Frontotemporal dementia:clinicopathological correlations[J]. Ann Neurol, 2006, 59:952-962.
[10] Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers[J]. Lancet Neurol, 2017, 16:661-676.
[11] Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ. Multicenter standardized ¹⁸F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias[J]. J Nucl Med, 2008, 49:390-398.
[12] Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME. Positron emission tomography in evaluation of dementia:regional brain metabolism and long-term outcome[J]. JAMA, 2001, 286:2120-2127.
[13] Sala A, Caprioglio C, Santangelo R, Vanoli EG, Iannaccone S, Magnani G, Perani D. Brain metabolic signatures across the Alzheimer's disease spectrum[J]. Eur J Nucl Med Mol Imaging, 2020, 47:256-269.
[14] Laforce R Jr, Soucy JP, Sellami L, Dallaire-Théroux C, Brunet F, Bergeron D, Miller BL, Ossenkoppele R. Molecular imaging in dementia:past, present, and future[J]. Alzheimers Dement, 2018, 14:1522-1552.
[15] Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment:a meta-analysis[J]. AJNR Am J Neuroradiol, 2009, 30:404-410.
[16] Caminiti SP, Ballarini T, Sala A, Cerami C, Presotto L, Santangelo R, Fallanca F, Vanoli EG, Gianolli L, Iannaccone S, Magnani G, Perani D; BIOMARKAPD Project. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort[J]. Neuroimage Clin, 2018, 18:167-177.
[17] Blazhenets G, Ma Y, Sörensen A, Schiller F, Rücker G, Eidelberg D, Frings L, Meyer PT; Alzheimer Disease Neuroimaging Initiative. Predictive value of ¹⁸F -Florbetapir and ¹⁸F -FDG PET for conversion from mild cognitive impairment to Alzheimer dementia[J]. J Nucl Med, 2020, 61:597-603.
[18] Ou YN, Xu W, Li JQ, Guo Y, Cui M, Chen KL, Huang YY, Dong Q, Tan L, Yu JT; Alzheimer's Disease. FDG-PET as an independent biomarker for Alzheimer's biological diagnosis:a longitudinal study[J]. Alzheimers Res Ther, 2019, 11:57.
[19] Xu L, Wu X, Li R, Chen K, Long Z, Zhang J, Guo X, Yao L; Alzheimer's Disease Neuroimaging Initiative. Prediction of progressive mild cognitive impairment by multi-modal neuroimaging biomarkers[J]. J Alzheimers Dis, 2016, 51:1045-1056.
[20] Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies:cerebral metabolic distinction with autopsy confirmation[J]. Ann Neurol, 2001, 50:358-365.
[21] Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, Albin RL, Koeppe RA, Kuhl DE. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity[J]. J Nucl Med, 1997, 38:797-802.
[22] Shimizu S, Hanyu H, Hirao K, Sato T, Iwamoto T, Koizumi K. Value of analyzing deep gray matter and occipital lobe perfusion to differentiate dementia with Lewy bodies from Alzheimer's disease[J]. Ann Nucl Med, 2008, 22:911-916.
[23] Gjerum L, Frederiksen KS, Henriksen OM, Law I, Anderberg L, Andersen BB, Bjerregaard E, Hejl AM, Høgh P, Hasselbalch SG. A visual rating scale for cingulate island sign on ¹⁸F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer's disease[J]. J Neurol Sci, 2020, 410:116645.
[24] Caminiti SP, Sala A, Iaccarino L, Beretta L, Pilotto A, Gianolli L, Iannaccone S, Magnani G, Padovani A, Ferini-Strambi L, Perani D. Brain glucose metabolism in Lewy body dementia:implications for diagnostic criteria[J]. Alzheimers Res Ther, 2019, 11:20.
[25] Shang K, Lu J, Li Z, Shuai DM, Su YS. Value of brain ¹⁸F-FDG PET/CT in differential diagnosis of AD and frontotemporal dementia[J]. Zhonghua Lao Nian Xin Nao Xue Guan Bing Za Zhi, 2019, 21:1297-1300.[尚琨, 卢洁, 李则, 帅冬梅, 苏玉盛. ¹⁸F氟脱氧葡萄糖正电子发射断层显像鉴别阿尔茨海默病和额颞叶痴呆的价值[J]. 中华老年心脑血管病杂志, 2019, 21:1297-1300.]
[26] Diehl-Schmid J, Onur OA, Kuhn J, Gruppe T, Drzezga A. Imaging frontotemporal lobar degeneration[J]. Curr Neurol Neurosci Rep, 2014, 14:489.
[27] Tosun D, Schuff N, Rabinovici GD, Ayakta N, Miller BL, Jagust W, Kramer J, Weiner MM, Rosen HJ. Diagnostic utility of ASL-MRI and FDG-PET in the behavioral variant of FTD and AD[J]. Ann Clin Transl Neurol, 2016, 3:740-751.
[28] Matias-Guiu JA, Cabrera-Martín MN, García-Ramos R, Moreno-Ramos T, Valles-Salgado M, Carreras JL, Matias-Guiu J. Evaluation of the new consensus criteria for the diagnosis of primary progressive aphasia using fluorodeoxyglucose positron emission tomography[J]. Dement Geriatr Cogn Disord, 2014, 38:147-152.
[29] Heiss WD, Zimmermann-Meinzingen S. PET imaging in the differential diagnosis of vascular dementia[J]. J Neurol Sci, 2012, 322:268-273.
[30] Perini G, Rodriguez-Vieitez E, Kadir A, Sala A, Savitcheva I, Nordberg A. Clinical impact of (18)F-FDG-PET among memory clinic patients with uncertain diagnosis[J]. Eur J Nucl Med Mol Imaging, 2021, 48:612-622.
[31] Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease:revising the NINCDS-ADRDA criteria[J]. Lancet Neurol, 2007, 6:734-746.
[32] Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer's disease:the IWG-2 criteria[J]. Lancet Neurol, 2014, 13:614-629.
[33] McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies:fourth consensus report of the DLB consortium[J]. Neurology, 2017, 89:88-100.
[34] Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia[J]. Brain, 2011, 134(Pt 9):2456-2477.
[35] Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M. Classification of primary progressive aphasia and its variants[J]. Neurology, 2011, 76:1006-1014.
[36] Olsen KM, Manouchehr-Pour S, Donnelly EF, Henry TS, Berry MF, Boiselle PM, Colletti PM, Harrison NE, Kuzniewski CT, Laroia AT, Maldonado F, Pinchot JW, Raptis CA, Shim K, Tong BC, Wu CC, Kanne JP; Expert Panel on Thoracic Imaging. ACR Appropriateness Criteria ^® Hemoptysis[J]. J Am Coll Radiol, 2020, 17(5S):148-159.
[37] Iaccarino L, Sala A, Perani D; Alzheimer's Disease Neuroimaging Initiative. Predicting long-term clinical stability in amyloid -positive subjects by FDG -PET[J]. Ann Clin Transl Neurol, 2019, 6:1113-1120.
[38] Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ; Amyloid PET Study Group, Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jagust WJ, Miller BL, Rosen HJ, Landau SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin M, Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, Vandenberghe R, van Laere K, Drzezga A, Forster S, Grimmer T, Sánchez-Juan P, Carril JM, Mok V, Camus V, Klunk WE, Cohen AD, Meyer PT, Hellwig S, Newberg A, Frederiksen KS, Fleisher AS, Mintun MA, Wolk DA, Nordberg A, Rinne JO, Chételat G, Lleo A, Blesa R, Fortea J, Madsen K, Rodrigue KM, Brooks DJ. Prevalence of amyloid PET positivity in dementia syndromes:a meta-analysis[J]. JAMA, 2015, 313:1939-1949.
[39] Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM; AV45-A07 Study Group. Use of florbetapir-PET for imaging beta -amyloid pathology[J]. JAMA, 2011, 305:275-283.
[40] Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, Adler LP, Kovnat KD, Seibyl JP, Arora A, Saha K, Burns JD, Lowrey MJ, Mintun MA, Skovronsky DM; Florbetapir F 18 Study. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects[J]. J Nucl Med, 2012, 53:378-384.
[41] Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias[J]. J Nucl Med, 2011, 52:1210-1217.
[42] Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasi? JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand ¹⁸F-AV -45(Florbetapir F 18)[J]. J Nucl Med, 2010, 51:913-920.
[43] Fantoni ER, Chalkidou A, O'Brien JT, Farrar G, Hammers A. A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer's disease[J]. J Alzheimers Dis, 2018, 63:783-796.
[44] Falgàs N, Tort-Merino A, Balasa M, Borrego-Écija S, Castellví M, Olives J, Bosch B, Férnandez-Villullas G, Antonell A, Augé JM, Lomeña F, Perissinotti A, Bargalló N, Sánchez-Valle R, Lladó A. Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment[J]. Eur J Neurol, 2019, 26:1098-1104.
[45] Rice L, Bisdas S. The diagnostic value of FDG and amyloid PET in Alzheimer's disease:a systematic review[J]. Eur J Radiol, 2017, 94:16-24.
[46] Zhao YJ, Gan JH, Liu S, Hu WZ, Li ZL, Shi ZH, Ji Y. Significance of ¹¹C-PIB-PET examination in patients with cognitive impairment[J]. A Er Ci Hai Mo Bing Ji Xiang Guan Bing, 2019, 2:261-265.[赵玉瑾, 甘景环, 刘帅, 胡文政, 李张龙, 石志鸿, 纪勇. 认知障碍患者¹¹C-PIB-PET检查的意义[J]. 阿尔茨海默病及相关病, 2019, 2:261-265.]
[47] Thal DR, Rüb U, Orantes M, Braak H. Phases of a beta-deposition in the human brain and its relevance for the development of AD[J]. Neurology, 2002, 58:1791-1800.
[48] Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease[J]. Cereb Cortex, 1991, 1:103-116.
[49] Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease[J]. Brain, 2006, 129(Pt 11):2856-2866.
[50] Martínez G, Vernooij RW, Fuentes Padilla P, Zamora J, Bonfill Cosp X, Flicker L. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)[J]. Cochrane Database Syst Rev, 2017, 11:CD012216.
[51] Martínez G, Vernooij RW, Fuentes Padilla P, Zamora J, Flicker L, Bonfill Cosp X. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)[J]. Cochrane Database Syst Rev, 2017, 11:CD012884.
[52] Liu S, Wang XD, Wang Y, Shi Z, Cai L, Liu S, Han T, Zhou Y, Wang X, Gao S, Ji Y. Clinical and neuroimaging characteristics of Chinese dementia with Lewy bodies[J]. PLoS One, 2017, 12:e0171802.
[53] Frey KA, Petrou M. Imaging amyloidopathy in Parkinson disease and Parkinsonian dementia syndromes[J]. Clin Transl Imaging, 2015, 3:57-64.
[54] Kantarci K, Lowe VJ, Chen Q, Przybelski SA, Lesnick TG, Schwarz CG, Senjem ML, Gunter JL, Jack CR Jr, Graff-Radford J, Jones DT, Knopman DS, Graff-Radford N, Ferman TJ, Parisi JE, Dickson DW, Petersen RC, Boeve BF, Murray ME. beta-Amyloid PET and neuropathology in dementia with Lewy bodies[J]. Neurology, 2020, 94:e282-291.
[55] Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, Bormans G, Brooks DJ, Vandenberghe R. Phase 1 study of the Pittsburgh compound B derivative ¹⁸F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease[J]. J Nucl Med, 2009, 50:1251-1259.
[56] Kobylecki C, Langheinrich T, Hinz R, Vardy ER, Brown G, Martino ME, Haense C, Richardson AM, Gerhard A, Anton-Rodriguez JM, Snowden JS, Neary D, Pontecorvo MJ, Herholz K. ¹⁸F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease[J]. J Nucl Med, 2015, 56:386-391.
[57] Shi Z, Fu LP, Zhang N, Zhao X, Liu S, Zuo C, Cai L, Wang Y, Gao S, Ai L, Guan YH, Xu B, Ji Y. Amyloid PET in dementia syndromes:a Chinese multicenter study[J]. J Nucl Med, 2020, 61:1814-1819.
[58] Bouwman F, Orini S, Gandolfo F, Altomare D, Festari C, Agosta F, Arbizu J, Drzezga A, Nestor P, Nobili F, Walker Z, Morbelli S, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia[J]. Eur J Nucl Med Mol Imaging, 2018, 45:1526-1533.
[59] Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH. Appropriate use criteria for amyloid PET:a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association[J]. J Nucl Med, 2013, 54:476-490.
[60] Gao Y, Tan L, Yu JT, Tan L. Tau in Alzheimer's disease:mechanisms and therapeutic strategies[J]. Curr Alzheimer Res, 2018, 15:283-300.
[61] Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics:a retrospective study[J]. Lancet Neurol, 2011, 10:785-796.
[62] Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis[J]. Acta Neuropathol, 1996, 92:197-201.
[63] Novel Drug Approvals for 2020, 2020[EB/OL].[2021-03-08] https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020.
[64] Jonasson M, Wall A, Chiotis K, Saint-Aubert L, Wilking H, Sprycha M, Borg B, Thibblin A, Eriksson J, Sörensen J, Antoni G, Nordberg A, Lubberink M. Tracer kinetic analysis of (S)-¹⁸F-THK5117 as a PET tracer for assessing tau pathology[J]. J Nucl Med, 2016, 57:574-581.
[65] Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease[J]. Brain, 2016, 139(Pt 5):1551-1567.
[66] Zhang RQ, Chen SD, Shen XN, Yang YX, Lu JY, Cui M, Zuo CT, Dong Q, Tan L, Yu JT; Alzheimer's Disease Neuroimaging Initiative. Elevated Tau PET signal depends on abnormal amyloid levels and correlates with cognitive impairment in elderly persons without dementia[J]. J Alzheimers Dis, 2020, 78:395-404.
[67] Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TL, Ances BM. Tau and Abeta imaging, CSF measures, and cognition in Alzheimer's disease[J]. Sci Transl Med, 2016, 8:338ra66.
[68] Chételat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F, Vandenberghe R. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease[J]. Neuroimage Clin, 2013, 2:356-365.
[69] Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Jonasson M, Eriksson J, Lubberink M, Almkvist O, Wall A, Antoni G, Nordberg A. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm[J]. Eur J Nucl Med Mol Imaging, 2016, 43:1686-1699.
[70] Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, Lee JH, Ryu YH, Lee MS, Lyoo CH. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum[J]. Ann Neurol, 2016, 80:247-258.
[71] Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM, Lyoo CH, Ryu YH, Lee MS. Tau PET in Alzheimer disease and mild cognitive impairment[J]. Neurology, 2016, 87:375-383.
[72] Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Hiraoka K, Watanuki S, Shidahara M, Miyake M, Ishikawa Y, Matsuda R, Inami A, Yoshikawa T, Tago T, Funaki Y, Iwata R, Tashiro M, Yanai K, Arai H, Kudo Y.[(18) F] THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease[J]. Eur J Nucl Med Mol Imaging, 2015, 42:1052-1061.
[73] Ishiki A, Okamura N, Furukawa K, Furumoto S, Harada R, Tomita N, Hiraoka K, Watanuki S, Ishikawa Y, Tago T, Funaki Y, Iwata R, Tashiro M, Yanai K, Kudo Y, Arai H. Longitudinal assessment of Tau pathology in patients with Alzheimer's disease using[18F] THK-5117 positron emission tomography[J]. PLoS One, 2015, 10:e0140311.
[74] Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B, Gomez-Isla T, Hyman B, Vasdev N, Sperling R. Tau positron emission tomographic imaging in aging and early Alzheimer disease[J]. Ann Neurol, 2016, 79:110-119.
[75] Kimura Y, Ichise M, Ito H, Shimada H, Ikoma Y, Seki C, Takano H, Kitamura S, Shinotoh H, Kawamura K, Zhang MR, Sahara N, Suhara T, Higuchi M. PET quantification of tau pathology in human brain with ¹¹C-PBB3[J]. J Nucl Med, 2015, 56:1359-1365.
[76] Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using ¹⁸F-THK5105 PET[J]. Brain, 2014, 137(Pt 6):1762-1771.
[77] Schöll M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD, Jagust WJ. PET imaging of tau deposition in the aging human brain[J]. Neuron, 2016, 89:971-982.
[78] Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, Joshi AD, Devous MD Sr, Mintun MS. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages[J]. Brain, 2016, 139(Pt 5):1539-1550.
[79] Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Doré V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease[J]. Eur J Nucl Med Mol Imaging, 2014, 41:816-826.
[80] Smith R, Puschmann A, Schöll M, Ohlsson T, van Swieten J, Honer M, Englund E, Hansson O. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers[J]. Brain, 2016, 139(Pt 9):2372-2379.
[81] Su Y, Fu J, Yu J, Zhao Q, Guan Y, Zuo C, Li M, Tan H, Cheng X. Tau PET imaging with[18F] PM-PBB3 in frontotemporal dementia with MAPT mutation[J]. J Alzheimers Dis, 2020, 76:149-157.
[82] Gomperts SN, Locascio JJ, Makaretz SJ, Schultz A, Caso C, Vasdev N, Sperling R, Growdon JH, Dickerson BC, Johnson K. Tau positron emission tomographic imaging in the Lewy body diseases[J]. JAMA Neurol, 2016, 73:1334-1341.
[83] Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging:early progress and future directions[J]. Lancet Neurol, 2015, 14:114-124.
[84] Lois C, Gonzalez I, Johnson KA, Price JC. PET imaging of tau protein targets:a methodology perspective[J]. Brain Imaging Behav, 2019, 13:333-344.
[85] Villemagne VL. Selective tau imaging: der dinge[J]. der stand J Nucl Med, 2018, 59:175-176.
[86] Zhou WY, Zhao QH, Guo QH, Guan YH. Research progress of PET imaging targeting tau protein abnormalities in Alzheimer's disease[J]. Zhonghua Shen Jing Ke Za Zhi, 2016, 49:338-341.[周维燕, 赵倩华, 郭起浩, 管一晖. 阿尔茨海默病中以tau蛋白异常为靶点的PET显像研究进展[J]. 中华神经科杂志, 2016, 49:338-341.]
[87] Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, Stone CK, Rowley HA, Johnson SC, Christian BT. In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls[J]. J Nucl Med, 2019, 60:93-99.
[88] Lu J, Bao W, Li M, Li L, Zhang Z, Alberts I, Brendel M, Cumming P, Lu H, Xiao Z, Zuo C, Guan Y, Zhao Q, Rominger A. Associations of[18F]-APN-1607 tau PET binding in the brain of Alzheimer's disease patients with cognition and glucose metabolism[J]. Front Neurosci, 2020, 14:604.
[89] Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, Dhaher R, Matuskey D, Baum E, Holden D, Spencer DD, Mercier J, Hannestad J, Huang Y, Carson RE. Imaging synaptic density in the living human brain[J]. Sci Transl Med, 2016, 8:348ra96.
[90] Koole M, van Aalst J, Devrome M, Mertens N, Serdons K, Lacroix B, Mercier J, Sciberras D, Maguire P, Van Laere K. Quantifying SV2A density and drug occupancy in the human brain using[11C] UCB-J PET imaging and subcortical white matter as reference tissue[J]. Eur J Nucl Med Mol Imaging, 2019, 46:396-406.
[91] Cai Z, Li S, Zhang W, Pracitto R, Wu X, Baum E, Finnema SJ, Holden D, Toyonaga T, Lin SF, Lindemann M, Shirali A, Labaree DC, Ropchan J, Nabulsi N, Carson RE, Huang Y. Synthesis and preclinical evaluation of an 18F-labeled synaptic vesicle glycoprotein 2A PET imaging probe:[18F] SynVesT-2[J]. ACS Chem Neurosci, 2020, 11:592-603.
[92] Constantinescu CC, Tresse C, Zheng M, Gouasmat A, Carroll VM, Mistico L, Alagille D, Sandiego CM, Papin C, Marek K, Seibyl JP, Tamagnan GD, Barret O. Development and in vivo preclinical imaging of fluorine-18-labeled synaptic vesicle protein 2A (SV2A) PET tracers[J]. Mol Imaging Biol, 2019, 21:509-518.
[93] Hu XS, Okamura N, Arai H, Higuchi M, Matsui T, Tashiro M, Shinkawa M, Itoh M, Ido T, Sasaki H. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies[J]. Neurology, 2000, 55:1575-1577.
[94] Mavroudis I, Petridis F, Kazis D. Cerebrospinal fluid, imaging, and physiological biomarkers in dementia with Lewy bodies[J]. Am J Alzheimers Dis Other Demen, 2019, 34:421-432.
[95] Morbelli S, Chincarini A, Brendel M, Rominger A, Bruffaerts R, Vandenberghe R, Kramberger MG, Trost M, Garibotto V, Nicastro N, Frisoni GB, Lemstra AW, van der Zande J, Pilotto A, Padovani A, Garcia -Ptacek S, Savitcheva I, Ochoa -Figueroa MA, Davidsson A, Camacho V, Peira E, Arnaldi D, Bauckneht M, Pardini M, Sambuceti G, Aarsland D, Nobili F. Metabolic patterns across core features in dementia with lewy bodies[J]. Ann Neurol, 2019, 85:715-725.
[96] Stefaniak J, O'Brien J. Imaging of neuroinflammation in dementia:a review[J]. J Neurol Neurosurg Psychiatry, 2016, 87:21-28.
[97] Bradburn S, Murgatroyd C, Ray N. Neuroinflammation in mild cognitive impairment and Alzheimer's disease:a meta-analysis[J]. Ageing Res Rev, 2019, 50:1-8.
[98] Albrecht DS, Granziera C, Hooker JM, Loggia ML. In vivo imaging of human neuroinflammation[J]. ACS Chem Neurosci, 2016, 7:470-483.
[99] Zhong Y, Jin CT, Zhang MR, Zhang H. PET molecular imaging of neuroinflammation in Alzheimer's disease[J]. Guo Ji Fang She Yi Xue He Yi Xue Za Zhi, 2019, 43:503-509.[钟燕, 金晨涛, 张明荣, 张宏. PET分子影像在阿尔茨海默病神经炎症中的研究进展[J]. 国际放射医学核医学杂志, 2019, 43:503-509.]
[100] Gui Y, Marks JD, Das S, Hyman BT, Serrano-Pozo A. Characterization of the 18 kDa translocator protein (TSPO) expression in post-mortem normal and Alzheimer's disease brains[J]. Brain Pathol, 2020, 30:151-164.
[101] Wadsworth H, Jones PA, Chau WF, Durrant C, Fouladi N, Passmore J, O'Shea D, Wynn D, Morisson-Iveson V, Ewan A, Thaning M, Mantzilas D, Gausemel I, Khan I, Black A, Avory M, Trigg W.[18F] GE-180:a novel fluorine-18 labelled PET tracer for imaging Translocator protein 18 kDa (TSPO)[J]. Bioorg Med Chem Lett, 2012, 22:1308-1313.
[102] Ikawa M, Lohith TG, Shrestha S, Telu S, Zoghbi SS, Castellano S, Taliani S, Da Settimo F, Fujita M, Pike VW, Innis RB; Biomarkers Consortium Radioligand Project Team. ¹¹C-ER176, a radioligand for 18-kDa translocator protein, has adequate sensitivity to robustly image all three affinity genotypes in human brain[J]. J Nucl Med, 2017, 58:320-325.

Please choose a citation manager

Content to export